Takeda Pharmaceutical (TAK) Long-Term Investments (2017 - 2026)

Takeda Pharmaceutical's Long-Term Investments history runs 10 years deep, the most recent figure standing at $56.1 million for Q1 2026.

• In Q1 2026, Long-Term Investments fell 20.78% year-over-year to $56.1 million; the TTM figure through Mar 2026 stood at $56.1 million (down 20.78% YoY), while the FY2026 annual figure was $58.4 million, down 17.6% from the prior year.
• Long-Term Investments was $56.1 million for Q1 2026 at Takeda Pharmaceutical, down from $66.2 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $2.3 billion in Q1 2024 to a low of $56.1 million in Q1 2026.
• Historically, Long-Term Investments has averaged $622.7 million across 5 years, with a median of $668.4 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Long-Term Investments surged 154.42% in 2023, then tumbled 96.92% in 2025.
• A 5-year view of Long-Term Investments shows it stood at $668.4 million in 2022, then increased by 4.57% to $698.9 million in 2023, then tumbled by 88.06% to $83.5 million in 2024, then retreated by 20.69% to $66.2 million in 2025, then retreated by 15.28% to $56.1 million in 2026.
• The last three Long-Term Investments figures came in at $56.1 million (Q1 2026), $66.2 million (Q4 2025), and $60.5 million (Q3 2025), per Business Quant data.